NCT04284852已完成2 期
Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting - a Phase 2, Single-arm Trial (NEOPRIMA Trial)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- PFS rate at 18 months
研究概览
简要总结
This study aims to evaluate the effects of niraparib in those who have received neoadjuvant chemotherapy and subsequent interval debulking surgery, with or without hyperthermic intraperitoneal chemotherapy, and would also explore if there are any biomarkers, other than BRCA / HRD status and platinum sensitivity, that may help to identify those who may benefit from PARPi especially those who are HRD negative.
详细描述
Despite cytoreductive surgery and platinum-based chemotherapy, about 70% of patients with advanced ovarian cancer recur in the first 2 - 3 years. PARPi has been shown to be prolong survival in primary advanced ovarian cancer. However its role in neoadjuvant setting has not been fully evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must be at least 18 years old.
- •Patients must have newly diagnosed, histologically confirmed high grade, serous or endometrioid, FIGO stage 3 or 4, ovarian, fallopian tube or primary peritoneal carcinoma before the start of NACT.
- •Patients must have received 3 - 4 cycles of NACT containing either carboplatin or cisplatin, IDS with or without HIPEC, and 3 - 6 more cycles of adjuvant chemotherapy, prior to recruitment into the study.
- •The patients should have only one cytoreductive surgery.
- •The patients must show either complete (CR) or partial response (PR) to the platinum-based chemotherapy using RECIST 1.1 criteria.
- •Patients should not be amenable to further surgery or radiotherapy except for the purpose of symptomatic relief.
- •All surgery, chemotherapy and radiotherapy should finish more than 3 weeks prior to recruitment.
- •Niraparib should be started within 8 weeks after the last dose of chemotherapy.
- •Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment.
- •Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment.
- •Patients who have childbearing potential should practice highly effective contraception throughout the study until at least 30 days after completion of the treatment.
排除标准
- •Patients who are diagnosed to have low-grade or borderline carcinoma, mucinous or clear cell cystadenocarcinoma, carcinosarcoma or undifferentiated carcinoma, are excluded.
- •Patients who have stable disease or PD on the post-treatment scan or clinical evidence are excluded.
- •Patients who have drainage of ascites within 4 weeks before recruitment are excluded.
- •Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer or in-situ breast cancer) are excluded.
- •Patients who have history of unresolved thrombocytopenia, myelodysplastic syndrome or acute myeloid leukaemia are excluded.
- •Patients who have symptomatic brain or leptomeningeal metastases, or spinal cord compression are excluded unless these are treated and controlled within 28 days of recruitment.
- •Patients with the significant past medical history, such as active hepatitis, myocardiac infarction, in the last six months are excluded.
- •Patients with severe gastrointestinal conditions such as evidence of bowel obstruction in the last 4 weeks prior to enrolment, or history of inflammatory bowel disease, are not eligible.
- •Patients having had severe infections within 4 weeks prior to the start of treatment are excluded.
- •Patents with active tuberculosis, history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) are excluded.
- •Patients with prior allogeneic stem cell or solid organ transplantation are excluded.
- •Those patients who suffer from CTCAE grade 2 or more toxicity from previous treatment, except alopecia, are excluded.
- •Patients who have used PARPi previously are excluded.
- •Patients who are allergic to any component of niraparib are excluded.
- •Patients who have used bevacizumab, or who are going to use bevacizumab as maintenance, are not eligible to join the study.
- •Use of other investigational drugs within 28 days or at least 5 half-lives (whichever is longer) before study drug administration is not allowed.
- •Patients who are pregnant or breastfeeding are excluded.
- •Patients must not have either platelet or red blood cell transfusion, or granulocyte colony stimulating factor (G-CSF) within 2 weeks of the first dose of study treatment.
- •Patients must not plan to donate blood during the study or for 90 days after the last dose of study treatment.
- •Patients with major operation within 28 days or open biopsy within 7 days before enrolment are not eligible.
- •Patients planned to have major surgery during the course of the study are excluded.
研究组 & 干预措施
Experimental arm
Experimental
Niraparib 200 or 300mg daily orally for 18 cycles unless disease progression or intolerable side effects (whichever occurs first)
干预措施: Niraparib (Drug)
结局指标
主要结局
PFS rate at 18 months
时间窗: up to 18 months
Proportion of patients who are progression-free at 18 months according to the RECIST 1.1
次要结局
- PFS by the RECIST 1.1(up to 5 years)
- Change of biomarkers(up to 18 months)
- Treatment-related adverse events(up to 18 months)
- Overall survival(up to 5 years)
- OS rate at 18 months(up to 18 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric CancerGastric CancerNCT01444755Haydarpasa Numune Training and Research Hospital80
终止
2 期
Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal CancerRectal NeoplasmsNCT01613469Marks, John, M.D.5
招募中
2 期
Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial)Hyperthermic Intraperitoneal ChemotherapyNeoadjuvant ChemotherapyNCT05246020Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University80
撤回
早期 1 期
Niraparib in High-grade Endometrial Cancer TrialEndometrial CancerSerous AdenocarcinomaUterine NeoplasmNCT05289648Sir Mortimer B. Davis - Jewish General Hospital31
已完成
不适用
ocal recurrence after neoadjuvant chemotherapy among breast cancer-A multicenter retrospective cohort studybreast cancerJPRN-UMIN000041620Mie University Hospital200